{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,8]],"date-time":"2025-06-08T22:27:48Z","timestamp":1749421668229},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,10,1]],"date-time":"2016-10-01T00:00:00Z","timestamp":1475280000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100001412","name":"Council of Scientific and Industrial Research","doi-asserted-by":"crossref","award":["BSC0205"],"award-info":[{"award-number":["BSC0205"]}],"id":[{"id":"10.13039\/501100001412","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pulmonary Pharmacology & Therapeutics"],"published-print":{"date-parts":[[2016,10]]},"DOI":"10.1016\/j.pupt.2016.06.009","type":"journal-article","created":{"date-parts":[[2016,7,26]],"date-time":"2016-07-26T13:00:59Z","timestamp":1469538059000},"page":"44-51","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Preclinical comprehensive physicochemical and pharmacokinetic profiling of novel nitroimidazole derivative IIIM-019 \u2013 A potential oral treatment for tuberculosis"],"prefix":"10.1016","volume":"40","author":[{"given":"Gurleen","family":"Kour","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anil","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Parvinder Pal","family":"Singh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sumit","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Asha","family":"Bhagat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ram A.","family":"Vishwakarma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zabeer","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.pupt.2016.06.009_bib1","series-title":"Global Tuberculosis Report. WHO\/HTM\/TB\/2014.08","author":"World Health Organization (WHO)","year":"2014"},{"key":"10.1016\/j.pupt.2016.06.009_bib2","series-title":"Equity, Social Determinants and Public Health Programmes","first-page":"221","article-title":"Tuberculosis: the role of risk factors and social determinants","author":"Lonnroth","year":"2010"},{"key":"10.1016\/j.pupt.2016.06.009_bib3","series-title":"Treatment of Tuberculosis: Guidelines for National Programmes","author":"World Health Organization (WHO)","year":"2009"},{"key":"10.1016\/j.pupt.2016.06.009_bib4","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1371\/journal.pmed.0030466","article-title":"OPC-67683, a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in\u00a0vitro and in mice","volume":"3","author":"Matsumoto","year":"2006","journal-title":"PLoS. Med."},{"key":"10.1016\/j.pupt.2016.06.009_bib5","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1007\/s40265-014-0241-5","article-title":"Delamanid: first global approval","volume":"74","author":"Ryan","year":"2014","journal-title":"Drugs"},{"key":"10.1016\/j.pupt.2016.06.009_bib6","series-title":"PA-824-CL-007: Phase IIa Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis","author":"National Library of Medicine","year":"2014"},{"key":"10.1016\/j.pupt.2016.06.009_bib7","doi-asserted-by":"crossref","first-page":"949","DOI":"10.5588\/ijtld.10.0616","article-title":"Early bactericidal activity of delamanid (OPC-67683) in smear-positive pulmonary tuberculosis patients","volume":"15","author":"Diacon","year":"2011","journal-title":"Int. J. Tuberc. Lung Dis."},{"key":"10.1016\/j.pupt.2016.06.009_bib8","doi-asserted-by":"crossref","first-page":"3402","DOI":"10.1128\/AAC.01354-09","article-title":"Early bactericidal activity and pharmacokinetics of PA-824 in smear-positive tuberculosis patients","volume":"54","author":"Diacon","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.pupt.2016.06.009_bib9","doi-asserted-by":"crossref","first-page":"3610","DOI":"10.1039\/C5OB00054H","article-title":"Synthesis of new generation triazolyl- and isoxazolyl-containing 6-nitro-2,3-dihydroimidazooxazoles as anti-TB agents: in\u00a0vitro, structure-activity relationship, pharmacokinetics and in\u00a0vivo evaluation","volume":"13","author":"Munagala","year":"2015","journal-title":"Org. Biomol. Chem."},{"key":"10.1016\/j.pupt.2016.06.009_bib10","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1038\/nrd1470","article-title":"Can the pharmaceutical industry reduce attrition rates?","volume":"3","author":"Kala","year":"2004","journal-title":"Nat. Rev. Drug. Discov."},{"key":"10.1016\/j.pupt.2016.06.009_bib11","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1038\/nature09657","article-title":"The challenge of new drug discovery for tuberculosis","volume":"469","author":"Koul","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.pupt.2016.06.009_bib12","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0169-409X(00)00129-0","article-title":"Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings","volume":"46","author":"Lipinski","year":"2001","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.pupt.2016.06.009_bib13","series-title":"Methods in Pharmacology and Toxicology","article-title":"Optimization in drug discovery: in\u00a0vitro methods","author":"Yan","year":"2004"},{"key":"10.1016\/j.pupt.2016.06.009_bib14","series-title":"Oral Drug Absorption, Prediction and Assessment","first-page":"137","article-title":"Solubility as a limiting factor to drug absorption","author":"L\u00f6benberg","year":"2000"},{"key":"10.1016\/j.pupt.2016.06.009_bib15","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1124\/dmd.104.000125","article-title":"Substrate depletion approach for determining in\u00a0vitro metabolic clearance: time dependencies in hepatocyte and microsomal incubations","volume":"32","author":"Jones","year":"2004","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.pupt.2016.06.009_bib16","series-title":"Principles and Methods of Toxicity","first-page":"77","article-title":"Metabolism: a determinant in toxicity","author":"DeBethizy","year":"2001"},{"key":"10.1016\/j.pupt.2016.06.009_bib17","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1164\/rccm.200206-626OC","article-title":"Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis","volume":"167","author":"Yee","year":"2003","journal-title":"Am. J. Respir. Crit. Care. Med"},{"key":"10.1016\/j.pupt.2016.06.009_bib18","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1183\/09031936.96.09102026","article-title":"Risk factors for side-effects of isoniazid, rifampin and pyrazinamide in patients hospitalized for pulmonary tuberculosis","volume":"9","author":"Schaberg","year":"1996","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.pupt.2016.06.009_bib19","first-page":"64","article-title":"Novel approach to drug discovery in PLIVA \u2013 Establishing of HTS unit and unique compounds library","volume":"2","author":"Jelic","year":"2003","journal-title":"Pharma. Chem."},{"key":"10.1016\/j.pupt.2016.06.009_bib20","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1093\/jac\/dku457","article-title":"Comprehensive physicochemical, pharmacokinetic and activity profiling of anti-TB agents","volume":"70","author":"Lakshminarayana","year":"2015","journal-title":"J.\u00a0Antimicrob. Chemother."},{"key":"10.1016\/j.pupt.2016.06.009_bib21","doi-asserted-by":"crossref","first-page":"4872","DOI":"10.1016\/j.bmcl.2008.07.071","article-title":"Physiochemical drug properties associated with in\u00a0vivo toxicological outcomes","volume":"18","author":"Hughes","year":"2008","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.pupt.2016.06.009_bib22","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1517\/17460441003605098","article-title":"Liphophilicity in drug discovery","volume":"5","author":"Waring","year":"2010","journal-title":"Expert Opin. Drug Discov."},{"key":"10.1016\/j.pupt.2016.06.009_bib23","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1002\/jps.21494","article-title":"Calculation of molecular lipophilicity: state-of-the-art and comparison of log P methods on more than 96,000 compounds","volume":"98","author":"Mannhold","year":"2009","journal-title":"J.\u00a0Pharm. Sci."},{"key":"10.1016\/j.pupt.2016.06.009_bib24","doi-asserted-by":"crossref","first-page":"4663","DOI":"10.1248\/cpb.34.4663","article-title":"A\u00a0method for calculation of the aqueous solubility of organic compounds by using new fragment solubility constants","volume":"34","author":"Wakita","year":"1986","journal-title":"Chem. Pharm. Bull."},{"key":"10.1016\/j.pupt.2016.06.009_bib25","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1038\/nrd3287","article-title":"The effect of plasma protein binding on in\u00a0vivo efficacy: misconceptions in drug discovery","volume":"9","author":"Dennis","year":"2010","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.pupt.2016.06.009_bib26","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.jpba.2016.02.027","article-title":"Development and validation of a highly sensitive LC-MS\/MS-ESI method for quantification of IIIM-019-a novel nitroimidazole derivative with promising action against tuberculosis: application to drug development","volume":"124","author":"Kour","year":"2016","journal-title":"J.\u00a0Pharm. Biomed. Anal."}],"container-title":["Pulmonary Pharmacology & Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1094553916300499?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1094553916300499?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,10]],"date-time":"2018-09-10T07:24:50Z","timestamp":1536564290000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1094553916300499"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10]]},"references-count":26,"alternative-id":["S1094553916300499"],"URL":"https:\/\/doi.org\/10.1016\/j.pupt.2016.06.009","relation":{},"ISSN":["1094-5539"],"issn-type":[{"value":"1094-5539","type":"print"}],"subject":[],"published":{"date-parts":[[2016,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Preclinical comprehensive physicochemical and pharmacokinetic profiling of novel nitroimidazole derivative IIIM-019 \u2013 A potential oral treatment for tuberculosis","name":"articletitle","label":"Article Title"},{"value":"Pulmonary Pharmacology & Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pupt.2016.06.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}